Excited to be at the Rare Diseases Industry Accelerator Day « getting cilia moving » organized by @PCDresearch in London today. Amazing line up of speakers. It will be a great day!
https://t.co/TNuFRwL5II
@mrjamesob hi heard you have been discussing about teenagers and smart phones, social media and fake news. We are holding a charity event with Alex Mahon CEO @Channel4 discussing this very topic with Hattie Brett (editor of @GraziaUK.
https://t.co/Euz2etn7cN
@lifearc1 Such an inspirational initiative that will have amazing impact for the rare disease community. As Founder and Chair of @PCDresearch I was honoured to speak at this event about #primaryciliarydyskinesia and the challenges of rare disease.
Last night we hosted the official launch of our #RareDiseaseTranslational Challenge.
We'd like to say a huge thank you to those who attended the reception and thank our speakers for delivering inspiring talks throughout the evening.
https://t.co/JaIJLbaEdC
#RDTC#LifeArc2030
Today is #RareDiseaseDay! We are proud to participate in this campaign to raise awareness of rare diseases. The ultimate aim is to reach equity in social opportunity, healthcare and access to diagnosis for all people with a rare disease. This all starts with raised awareness!
Together with the MRC funded Nucleic Acid Therapy Accelerator (NATA) we are delighted to inform you that we will fund a two-year post-doctoral fellowship (£200,000) to start Q3 2023. Please read on for more details! 1/6
To be eligible, any overseas supervisors will need to partner with a supervisor based in the UK. The deadline for submissions is the 28th February, 2023.
We look forward to reading your exciting proposals! 6/6
Together with the MRC funded Nucleic Acid Therapy Accelerator (NATA) we are delighted to inform you that we will fund a two-year post-doctoral fellowship (£200,000) to start Q3 2023. Please read on for more details! 1/6
We are now looking for specific project proposals from people who would like to be a supervisor. If you would like to submit a proposal, please contact me (Dr. Harriet Holme) at: [email protected]. 5/6